諾華
NVS139.195USD
+0.315+0.23%
收盤 12/26, 16:00（美東）報價延遲15分鐘
267.09B總市值
18.90本益比TTM
關於 諾華 公司
諾華公司為瑞士總部的全球製藥巨頭，專注創新處方藥的研發、製造與行銷。公司現以單一 創新藥物 部門運營，聚焦免疫、腫瘤、神經、心血管、腎臟及代謝等治療領域，並運用數字平台加速臨床與商業決策。此前屬下的仿製藥與生物仿製藥業務已分拆為獨立公司 Sandoz，因此諾華資源得以全面投入先進療法與下一代技術平台。
諾華簡介
公司代碼NVS
公司名稱Novartis AG
上市日期May 07, 2001
CEONarasimhan (Vasant)
員工數量75883
證券類型Depository Receipt
年結日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家Switzerland
郵編4056
電話41613241111
網址https://www.novartis.com/
公司代碼NVS
上市日期May 07, 2001
CEONarasimhan (Vasant)
諾華公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
Ms. Charlotte Pamer- Wieser, Ph.D.
Ms. Charlotte Pamer- Wieser, Ph.D.
Corporate Secretary
Corporate Secretary
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal & Compliance Officer, Member of the Executive Committee
Chief Legal & Compliance Officer, Member of the Executive Committee
--
--
Mr. Frans van Houten
Mr. Frans van Houten
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Mr. Giovanni Caforio, M.D.
Mr. Giovanni Caforio, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Elizabeth (Liz) Doherty
Ms. Elizabeth (Liz) Doherty
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ton Buechner
Mr. Ton Buechner
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Aaron (Ronny) Gal, Ph.D.
Mr. Aaron (Ronny) Gal, Ph.D.
Chief Strategy and Growth Officer, Member of the Executive Committee
Chief Strategy and Growth Officer, Member of the Executive Committee
--
--
Mr. Victor Bulto
Mr. Victor Bulto
President - US, Member of the Executive Committee
President - US, Member of the Executive Committee
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
其他
5.34B
38.02%
地區USD
名稱
營收
佔比
US
6.25B
44.46%
Europe
4.17B
29.67%
Asia / Africa / Australasia
2.71B
19.30%
Canada and Latin America
922.00M
6.56%
業務
地區
業務USD
名稱
營收
佔比
Rest of portfolio
2.47B
17.58%
Cardiovascular, Renal and Metabolism - Entresto
2.36B
16.77%
Immunology - Cosentyx
1.63B
11.59%
Oncology -Kisqali
1.18B
8.37%
Neuroscience - Kesimpta
1.08B
7.66%
其他
5.34B
38.02%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
持股股東
持股股東
佔比
Dodge & Cox
0.55%
PRIMECAP Management Company
0.49%
Dimensional Fund Advisors, L.P.
0.46%
Fisher Investments
0.38%
Loomis, Sayles & Company, L.P.
0.30%
其他
97.83%
股東類型
持股股東
佔比
Investment Advisor
3.41%
Investment Advisor/Hedge Fund
2.86%
Research Firm
0.48%
Hedge Fund
0.20%
Bank and Trust
0.13%
Pension Fund
0.03%
Family Office
0.02%
其他
92.88%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
1967
135.58M
7.06%
-11.39M
2025Q2
1941
140.71M
7.27%
+2.13M
2025Q1
1953
141.07M
7.20%
+870.45K
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Dodge & Cox
10.65M
0.55%
-1.17M
-9.90%
Jun 30, 2025
PRIMECAP Management Company
10.40M
0.54%
+18.55K
+0.18%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
9.06M
0.47%
+454.17K
+5.28%
Jun 30, 2025
Fisher Investments
7.12M
0.37%
+358.28K
+5.30%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
5.58M
0.29%
+78.48K
+1.43%
Jun 30, 2025
Franklin Mutual Advisers, LLC
4.16M
0.21%
-702.88K
-14.45%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
3.65M
0.19%
+129.18K
+3.67%
Jun 30, 2025
Parametric Portfolio Associates LLC
3.08M
0.16%
+80.38K
+2.68%
Jun 30, 2025
Managed Account Advisors LLC
2.92M
0.15%
+7.18K
+0.25%
Jun 30, 2025
Aperio Group, LLC
2.24M
0.12%
+160.56K
+7.71%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
VanEck Pharmaceutical ETF
19.83%
Amplify International Enhanced Dividend Income ETF
3.67%
Abacus FCF International Leaders ETF
3.41%
Altrius Global Dividend ETF
2.39%
Invesco International Dividend Achievers ETF
2.08%
Freedom Day Dividend ETF
2.03%
Fundamentals First ETF
1.91%
SP Funds S&P World (ex-US) ETF
1.56%
DFA Dimensional Internatl High Profitability ETF
1.54%
Avantis Responsible International Equity ETF
1.35%
查看更多
VanEck Pharmaceutical ETF
佔比19.83%
Amplify International Enhanced Dividend Income ETF
佔比3.67%
Abacus FCF International Leaders ETF
佔比3.41%
Altrius Global Dividend ETF
佔比2.39%
Invesco International Dividend Achievers ETF
佔比2.08%
Freedom Day Dividend ETF
佔比2.03%
Fundamentals First ETF
佔比1.91%
SP Funds S&P World (ex-US) ETF
佔比1.56%
DFA Dimensional Internatl High Profitability ETF
佔比1.54%
Avantis Responsible International Equity ETF
佔比1.35%
分紅派息
近5年累計派現
36.74B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 20, 2025
NVS.NB Final Cash Dividend of gross USD 3.99399 paid on Apr 25, 2025 going ex on Mar 12, 2025
Mar 12, 2025
Apr 25, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
諾華的前五大股東是誰？
諾華的前五大股東如下：
Dodge & Cox持有股份：10.65M佔總股份比例：0.55%。
PRIMECAP Management Company持有股份：10.40M佔總股份比例：0.54%。
Dimensional Fund Advisors, L.P.持有股份：9.06M佔總股份比例：0.47%。
Fisher Investments持有股份：7.12M佔總股份比例：0.37%。
Loomis, Sayles & Company, L.P.持有股份：5.58M佔總股份比例：0.29%。
Dodge & Cox持有股份：10.65M佔總股份比例：0.55%。
PRIMECAP Management Company持有股份：10.40M佔總股份比例：0.54%。
Dimensional Fund Advisors, L.P.持有股份：9.06M佔總股份比例：0.47%。
Fisher Investments持有股份：7.12M佔總股份比例：0.37%。
Loomis, Sayles & Company, L.P.持有股份：5.58M佔總股份比例：0.29%。
諾華的前三大股東類型是什麼？
諾華 的前三大股東類型分別是：
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
Dodge & Cox
PRIMECAP Management Company
Dimensional Fund Advisors, L.P.
有多少機構持有諾華(NVS)的股份？
截至2025Q3，共有1967家機構持有諾華的股份，合計持有的股份價值約為135.58M，占公司總股份的7.06% 。與2025Q2相比，機構持股有所增加，增幅為-0.20%。
哪個業務部門對諾華的收入貢獻最大？
在FY2025Q2，Rest of portfolio業務部門對諾華的收入貢獻最大，創收2.47B，占總收入的17.58% 。
